TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer.
- Published in:
- Cancers, 2019, v. 11, n. 8, p. 1079, doi. 10.3390/cancers11081079
- By:
- Publication type:
- Article
Works matching AU Lapke, Nina
Results: 5
1
2
PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients.
- Published in:
- Cancers, 2018, v. 10, n. 9, p. 314, doi. 10.3390/cancers10090314
- By:
- Publication type:
- Article
3
Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
4
Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab.
- Published in:
- Case Reports in Oncological Medicine, 2020, p. 1, doi. 10.1155/2020/9072173
- By:
- Publication type:
- Article
5
Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer.
- Published in:
- Case Reports in Oncological Medicine, 2019, p. 1, doi. 10.1155/2019/6545298
- By:
- Publication type:
- Article